All In Biotech

Drug Trial Radar · NCT00387309

Study Evaluating IV Methylnaltrexone for the Treatment of Post Operative Ileus

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Intravenous Methylnaltrexone (MOA-728) for the Treatment of Post Operative Ileus.

Last checked: Nov 19, 2026Latest source record: Nov 25, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 495 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

495

Actual

Start

Dec 2006

Primary completion

Not stated

Study completion Nov 2007

Sponsor

Lead sponsor
Bausch Health Americas, Inc.Industry
Sponsor type
Industry
First posted
Oct 13, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: In subjects who have undergone segmental colectomy, the time between the end of surgery and first bowel movement is significantly shorter with the investigational MOA-728 regimen than with a placebo regimen.

Conditions

  • Post Operative Bowel Dysfunction

Interventions

  • Methylnaltrexone (MOA-728)Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Objective: In subjects who have undergone segmental colectomy, the time between the end of surgery and first bowel movement is significantly shorter with the MOA-728 regimen than with a placebo regimen.

Locations

92 sites in 10 countries. Site status is shown where the registry gives one.

  • Site not named

    Mobile, Alabama

  • Site not named

    Fort Smith, Arkansas

  • Site not named

    Chula Vista, California

  • Site not named

    Colton, California

  • Site not named

    Los Angeles, California

  • Site not named

    Oceanside, California

  • Site not named

    Palo Alto, California

  • Site not named

    San Jose, California

  • Site not named

    Torrance, California

  • Site not named

    Denver, Colorado

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    Bay Minette, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Melbourne, Florida

  • Site not named

    Naples, Florida

  • Site not named

    St. Petersburg, Florida

  • Site not named

    Vero Beach, Florida

  • Site not named

    Weston, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Atlanta, Georgia

  • Site not named

    Marietta, Georgia

  • Site not named

    Chicago, Illinois

  • Site not named

    Chicago, Illinois

  • Site not named

    Naperville, Illinois

  • Site not named

    Park Ridge, Illinois

  • Site not named

    Kansas City, Kansas

  • Site not named

    Lexington, Kentucky

  • Site not named

    New Orleans, Louisiana

  • Site not named

    Hagerstown, Maryland

  • Site not named

    Boston, Massachusetts

  • Site not named

    Saint Paul, Minnesota

  • Site not named

    Saint Paul, Minnesota

  • Site not named

    Albany, New York

  • Site not named

    Kingston, New York

  • Site not named

    New York, New York

  • Site not named

    New York, New York

  • Site not named

    Syracuse, New York

  • Site not named

    Chapel Hill, North Carolina

  • Site not named

    Cleveland, Ohio

  • Site not named

    Columbus, Ohio

Showing 40 of 92 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.